Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3328)	6/21/1999 5:27:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Interesting that SEPR news briefs has not included the JNJ withdrawal. Yet, we hear when JNJ retreats from marketing Nori., Hismanal's replacement. Is it norI or norA?

To: Biomaven who wrote (3328)	6/21/1999 5:45:00 PM
From: IRWIN JAMES FRANKEL	Respond to of 10280

Thanks Peter, I agree with you but wonder if there would have been any sales of Hismanal by 2001 when norastemizole reaches market. If memory serves me, Hismanal was once a $1+ billion drug that is now down to $100 million. I do have one employee who says nothing worked for him like Hismanal and he regrets the loss of it. If there are many like him out there they will want to try the new "Hismanal +" [closer the name used the easier to make the connection] once assured that the side effects have been eliminated. ij